These include PDK1 inhibitors (to prevent AktT308 phosphorylation and non-PI3K dependent phosphorylation of other kinases that can promote cancer progression), SHIP agonists (to promote PIP3 degradation), and heat shock protein inhibitors (Akt is a client protein of the molecular chaperone). The gene discussed is PIK3CD; the disease is cancer.